Excess Healthcare Costs and Resource Utilisation of Lyme Borreliosis in Germany: A Propensity Score-Matched Cohort Study.

IF 2.4 2区农林科学 Q3 INFECTIOUS DISEASES

Zoonoses and Public Health Pub Date : 2024-09-05 DOI:10.1111/zph.13180

Gordon Brestrich, Joanna Diesing, Nils Kossack, James H Stark, Andreas Pilz, Holly Yu, Jochen Suess

{"title":"Excess Healthcare Costs and Resource Utilisation of Lyme Borreliosis in Germany: A Propensity Score-Matched Cohort Study.","authors":"Gordon Brestrich, Joanna Diesing, Nils Kossack, James H Stark, Andreas Pilz, Holly Yu, Jochen Suess","doi":"10.1111/zph.13180","DOIUrl":null,"url":null,"abstract":"Aim: Lyme borreliosis (LB) is the most common tick-borne disease in Germany; however, data on the economic burden of LB are limited. In this study, we aim to report healthcare costs, healthcare resource utilisation (HCRU) and diagnostic consumption associated with LB by clinical manifestation.Method: Using specific case definitions, patients with localised disease (erythema migrans [EM]) or disseminated disease (Lyme arthritis [LA], Lyme neuroborreliosis [LNB] and other rarer manifestations [OTH]) were identified from a claims database in 2016 and followed up for 3 years (2016-2019). After propensity score matching, excess costs and HCRU were calculated as the differences between each LB cohort and the matched control cohort.Results: On a per-patient basis, the excess all-cause healthcare cost was €130 for EM during Quarter 1 of Year 1, and €1539 for LA, €3248 for LNB and €4137 for OTH during Year 1. Only for OTH, additional €1860 was observed in Year 2. No increase in costs was observed in Year 3. When extrapolated to all German patients with statutory health insurance, LB was associated with €64.5 million in excess costs. Although disseminated manifestations only accounted for 7.8% of all LB cases, they were responsible for 66% of overall costs. In addition, LB patients consumed healthcare resources of 1.4 million excess outpatient visits, 13,000 excess hospitalisations, 96,000 ELISAs and 65,000 Western blots.Conclusion: This study shows the substantial economic burden of LB to the German healthcare system.","PeriodicalId":24025,"journal":{"name":"Zoonoses and Public Health","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zoonoses and Public Health","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/zph.13180","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Lyme borreliosis (LB) is the most common tick-borne disease in Germany; however, data on the economic burden of LB are limited. In this study, we aim to report healthcare costs, healthcare resource utilisation (HCRU) and diagnostic consumption associated with LB by clinical manifestation.

Method: Using specific case definitions, patients with localised disease (erythema migrans [EM]) or disseminated disease (Lyme arthritis [LA], Lyme neuroborreliosis [LNB] and other rarer manifestations [OTH]) were identified from a claims database in 2016 and followed up for 3 years (2016-2019). After propensity score matching, excess costs and HCRU were calculated as the differences between each LB cohort and the matched control cohort.

Results: On a per-patient basis, the excess all-cause healthcare cost was €130 for EM during Quarter 1 of Year 1, and €1539 for LA, €3248 for LNB and €4137 for OTH during Year 1. Only for OTH, additional €1860 was observed in Year 2. No increase in costs was observed in Year 3. When extrapolated to all German patients with statutory health insurance, LB was associated with €64.5 million in excess costs. Although disseminated manifestations only accounted for 7.8% of all LB cases, they were responsible for 66% of overall costs. In addition, LB patients consumed healthcare resources of 1.4 million excess outpatient visits, 13,000 excess hospitalisations, 96,000 ELISAs and 65,000 Western blots.

Conclusion: This study shows the substantial economic burden of LB to the German healthcare system.

查看原文本刊更多论文

德国莱姆病的超额医疗成本和资源利用：倾向得分匹配队列研究》。

目的：莱姆包虫病（Lyme borreliosis，LB）是德国最常见的蜱媒疾病；然而，有关 LB 经济负担的数据却很有限。在这项研究中，我们旨在按临床表现报告与莱姆病相关的医疗成本、医疗资源利用率（HCRU）和诊断消耗：采用特定的病例定义，从2016年的理赔数据库中确定了局部疾病（迁徙性红斑[EM]）或播散性疾病（莱姆关节炎[LA]、莱姆神经性包虫病[LNB]和其他罕见表现[OTH]）患者，并对其进行了为期3年（2016-2019年）的随访。经过倾向得分匹配后，计算出每个 LB 队列与匹配对照队列之间的超额费用和 HCRU 差异：按每名患者计算，EM 在第一年第一季度的超额全因医疗成本为 130 欧元，LA 为 1539 欧元，LNB 为 3248 欧元，OTH 为 4137 欧元。只有 OTH 在第二年增加了 1860 欧元。第 3 年的费用没有增加。推断所有德国法定医疗保险患者的情况，LB 会带来 6450 万欧元的超额费用。虽然播散性表现只占所有枸杞病例的 7.8%，但却占总费用的 66%。此外，枸杞病患者还多花费了140万次门诊就诊、1.3万次住院治疗、9.6万次酶联免疫吸附试验和6.5万次免疫印迹等医疗资源：这项研究表明，枸橼酸结肠炎给德国医疗系统造成了巨大的经济负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Zoonoses and Public Health 医学-传染病学

CiteScore

5.30

自引率

4.20%

发文量

115

审稿时长

6-12 weeks

期刊介绍： Zoonoses and Public Health brings together veterinary and human health researchers and policy-makers by providing a venue for publishing integrated and global approaches to zoonoses and public health. The Editors will consider papers that focus on timely collaborative and multi-disciplinary research in zoonoses and public health. This journal provides rapid publication of original papers, reviews, and potential discussion papers embracing this collaborative spirit. Papers should advance the scientific knowledge of the sources, transmission, prevention and control of zoonoses and be authored by scientists with expertise in areas such as microbiology, virology, parasitology and epidemiology. Articles that incorporate recent data into new methods, applications, or approaches (e.g. statistical modeling) which enhance public health are strongly encouraged.